Clinical Trials Browser

Phase 2 × OTHER × eprenetapopt × Clear all

NCT04990778 2022-03-10

Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma

Phase 2 Withdrawn

Lymphoma, Mantle-Cell